IX Biopharma's (SGX:42C) net loss narrowed to SG$6.3 million for the half year ended Dec. 31, 2024, from SG$7.3 million a year earlier, a filing with the Singapore Exchange said on Friday.
Basic loss per share came in at SG$0.0072 from SG$0.0096 in the comparable period.
Revenue jumped 39% year over year to SG$3.7 million from SG$2.7 million, driven by stronger sales of medicinal cannabis products and services in Australia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.